Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

"Participants will receive study drug (Tirzepatide) according to the dose titration plan described in the FDA-approved Prescribing Information (starting with 2.5 mg/wk and increasing the dose every 4 weeks by increments of 2.5 mg.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."

"Participant's will continue on participant's regular diabetic and hypertriglyceridemia medications that were used during the run-in period for 24 weeks. This will be either Phase 1 or Phase 2 based on randomization.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."